한국어
English
日本語
中文(简体)
Linburk Sustained Release Tablet 15 mg (Upadacitinib Monohydrate)
15.4mg
Tablet · Prescription medication
AbbVie Korea Co., Ltd.
Upadacitinib monohydrate is an immunomodulator for the treatment of autoimmune diseases.
MFDS ingredient code M270797
Upadacitinib monohydrate is a drug belonging to the Janus kinase (JAK) inhibitor class. It is primarily used for the treatment of autoimmune diseases such as rheumatoid arthritis, and is used to reduce inflammation through non-specific immune suppression.
This ingredient blocks the JAK enzymes that are responsible for signaling within immune cells, thereby suppressing excessive immune responses and inflammation. This helps alleviate joint inflammation and pain associated with autoimmune diseases.
Approved uses differ by product. Check each product's information for its actual use.
Upadacitinib monohydrate has selective inhibition characteristics compared to other JAK inhibitors, helping to reduce the risk of side effects. Additionally, it can be taken orally, enhancing patient convenience.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.
